DXSE:XETRA:XETRA-Xtrackers - Stoxx Europe 600 Health Care Swap UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 215.15

Change

-0.65 (-0.30)%

Market Cap

USD 0.14B

Volume

179.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+1.07 (+2.05%)

USD 446.30B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.35 (+2.04%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.44 (+1.61%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.44 (+1.54%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.42 (+1.68%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+0.04 (+0.03%)

USD 102.09B
JARI:XETRA Amundi Index Solutions - Amund..

+0.86 (+1.91%)

USD 101.20B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+1.08 (+2.07%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+1.78 (+1.71%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+9.98 (+1.66%)

USD 80.38B

ETFs Containing DXSE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.52% 35% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.52% 34% F 39% F
Trailing 12 Months  
Capital Gain 4.52% 35% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.52% 34% F 39% F
Trailing 5 Years  
Capital Gain 33.09% 62% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.09% 58% F 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 9.77% 65% D 64% D
Dividend Return 9.77% 64% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.59% 68% D+ 75% C
Risk Adjusted Return 113.76% 97% N/A 97% N/A
Market Capitalization 0.14B 39% F 35% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.